Cyrus S. Poonawalla

Pune, MH, India

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Safety and Preliminary Efficacy of Dengue Monoclonal Antibody in Adult Patients: A Randomized Clinical Trial.

Safety and Preliminary Efficacy of Dengue Monoclonal Antibody in Adult Patients: A Randomized Clinical Trial.

Journal: JAMA network open
Published: August 25, 2026

Immunogenicity and safety of a dose-sparing inactivated poliovirus vaccine in infants in India: a phase 2/3, double-blind, randomised controlled trial.

Immunogenicity and safety of a dose-sparing inactivated poliovirus vaccine in infants in India: a phase 2/3, double-blind, randomised controlled trial.

Journal: The Lancet. Infectious diseases
Published: December 13, 2025

Nasopharyngeal pneumococcal carriage in Indian children following 10-valent PCV (PNEUMOSIL®) introduction through India's universal immunization program: A post licensure cross-sectional study.

Nasopharyngeal pneumococcal carriage in Indian children following 10-valent PCV (PNEUMOSIL®) introduction through India's universal immunization program: A post licensure cross-sectional study.

Journal: Vaccine
Published: October 09, 2025

Immunogenicity and non-inferiority evaluation of dose-sparing adjuvanted inactivated polio vaccine in Wistar rats.

Immunogenicity and non-inferiority evaluation of dose-sparing adjuvanted inactivated polio vaccine in Wistar rats.

Journal: Vaccine
Published: July 28, 2025

Safety and immunogenicity of a reduced-dose inactivated poliovirus vaccine versus a full-dose inactivated poliovirus vaccine in infants in Bangladesh: a double-blind, non-inferiority, randomised, controlled, phase 3 trial.

Safety and immunogenicity of a reduced-dose inactivated poliovirus vaccine versus a full-dose inactivated poliovirus vaccine in infants in Bangladesh: a double-blind, non-inferiority, randomised, controlled, phase 3 trial.

Journal: The Lancet. Infectious diseases
Published: January 16, 2025

Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial.

Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial.

Journal: Lancet (London, England)
Published: January 02, 2025

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 study.

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 study.

Journal: The Lancet. Infectious diseases
Published: June 05, 2024

Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.

Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.

Journal: Human vaccines & immunotherapeutics
Published: March 21, 2024

An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia.

An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia.

Journal: The Lancet. Infectious diseases
Published: October 04, 2023

The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.

The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.

Journal: Lancet (London, England)
Published: August 19, 2023

Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical Trial.

Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical Trial.

Journal: JAMA pediatrics
Published: July 31, 2023

Post-marketing safety surveillance of the rotavirus vaccine in India.

Post-marketing safety surveillance of the rotavirus vaccine in India.

Journal: Vaccine: X
Published: April 27, 2023
Showing 1-12 of 19

Last Updated: 09/26/2026